Article
Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation.
Blood - 1 Sept 2004
Christiansen Debes H, Andersen Mette K, Pedersen-Bjergaard Jens
Abstract excerpt
The AML1 transcription factor is essential for normal hematopoiesis and is the target of several chromosomal translocations in acute leukemia. Acquired somatic AML1 mutations were recently demonstrated sporadically in de novo myelodysplasia (MDS) and acute myeloid leukemia (AML) including a few cases of therapy-related disease (t-MDS/t-AML). We examined 140 patients with t-MDS or t-AML for AML1 mutations by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.